tradmap

KYMR Kymera Therapeutics, Inc.

$117.15 -1.24%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Kymera Therapeutics, Inc. (KYMR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $9.7 billion. Shares last traded at $117.15, 9.9% below their 52-week high. Over the past year the stock is up 170.9%. Net profit margin is -285.3%, below the peer median of 5.3%. Revenue declined 16.7% year over year.

Market Cap
$9.7B
Shares Out
83.2M
EPS (TTM)
$-6.52
P/E Ratio
P/S Ratio
92.77
P/B Ratio
6.45
Dividend / Share
Dividend Yield
52-Week High
$129.99
52-Week Low
$40.73
Volume
39,557
Avg Vol (3m)
59,827.429

Performance

1W
-2.41%
1M
+11.12%
3M
+57.10%
6M
+40.30%
YTD
+61.09%
1Y
+170.93%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
51.42
SMA (50)
$114.01
SMA (200)
$88.85
Price vs SMA50
+2.75%
Price vs SMA200
+31.86%
ATR (14)
$5.57

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$105M
Net Income
$-300M
Gross Margin
0.0%
Operating Margin
-333.5%
Net Margin
-285.3%
Return on Equity
-19.9%
Return on Assets
-18.2%
Current Ratio
10.34
Debt / Equity
0.09
Revenue Growth (YoY)
-16.7%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-1.33 2026-08-05
Q1 2026 $-0.71 2026-04-30
FY 2025 $-3.69 2026-02-26
Q3 2025 $-2.71 2025-11-04
Q2 2026 $-1.77 2026-08-05
Q1 2026 $-0.82 2026-04-30

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

KYMR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
92.77 / 19.49 med
+376% premium
Net margin vs peers
-285.3% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.